Advertisement
Advertisement
KAPA
Kairos Pharma, Ltd.
0.49
USDSponsored
+0.03
+7.33%
Nov 06, 15:59 UTC -5
Closed
After-Market
0.48
0.00
-0.80%
Kairos Pharma, Ltd. (KAPA) Earnings
KAPA Earnings Reports
Positive Surprise Ratio
KAPA beat 1 of 8 last estimates.
13%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Kairos Pharma, Ltd. earnings per share and revenue
On Aug 12, 2026, KAPA reported earnings of -0.42 USD per share (EPS) for Q2 26, beating the estimate of -0.57 USD, resulting in a 26.47% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.52% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were Kairos Pharma, Ltd.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Kairos Pharma, Ltd. reported EPS of -$0.42, beating estimates by 26.47%, and revenue of $0.00, 0% as expectations.
How did the market react to Kairos Pharma, Ltd.'s Q2 2026 earnings?
The stock price moved up 1.52%, changed from $0.35 before the earnings release to $0.36 the day after.
When is Kairos Pharma, Ltd. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Kairos Pharma, Ltd.'s next earnings report?
Based on --
analysts, Kairos Pharma, Ltd. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.